Vitrolife has agreed to acquire 100% of the shares in Igenomix from EQT and other shareholders. The merger creates a global leader in reproductive health care, combining the knowledge, products, and market position of two leading companies in fertility treatment and reproductive genetics testing.
Founded in 2011, Igenomix is a global leader in reproductive genetics testing for IVF clinics, with more than 250 laboratories worldwide and a broad product portfolio of clinically validated genetic tests and services. Headquartered in Spain with approximately 560 employees, the company has historically demonstrated profitable growth through innovation and global expansion.
Please read the press release from Vitrolife in its full here.